Superior Group of Companies (SGC) Q4 2025 earnings review
Cost Containment Drives Earnings Surge Despite Top-Line Weakness
Superior Group of Companies (SGC) finished 2025 with a mixed quarter: while revenue grew a meager 0.8% YoY, disciplined expense management fueled a 77% surge in Diluted EPS to $0.23. The company is leaning heavily on its Branded Products segment (+4.9% sales) to offset steep declines in Healthcare Apparel and Contact Centers. Management's aggressive $13 million annualized cost-cutting program launched earlier in the year has materialized, expanding Q4 EBITDA margins from 5.0% to 5.9%. Looking ahead to 2026, guidance suggests this dynamic will persist: revenue is projected to be stable with 1-3% growth, but earnings are accelerating with 17-43% projected EPS growth.
🐂 Bull Case
The company's cost-cutting initiatives have structurally improved profitability. Q4 SG&A expenses declined 2.8% YoY to $48.6M, which allowed a flat top line to translate into a 19% increase in consolidated EBITDA.
The largest segment, Branded Products, is accelerating. Revenue increased 4.9% YoY to $96.9M, and segment EBITDA surged 24%, validating management's strategy of aggressively pursuing market share in a fragmented industry.
🐻 Bear Case
Both Healthcare Apparel (-5.0% YoY) and Contact Centers (-8.0% YoY) are significantly lagging the company average. Until these segments stabilize, SGC's overall revenue growth will remain heavily constrained.
Management noted the company is emerging from 'uncertain times.' Previous quarters highlighted severe customer hesitancy and tariff concerns, which explains the highly conservative 1-3% revenue growth guidance for FY26.
⚖️ Verdict: ⚪
Neutral. The operational leverage and cost discipline are highly commendable and protect the bottom line. However, the top line is only being held up by one of three segments, presenting structural execution risks.
Key Themes
Structural Cost Reductions Deliver Operating Leverage
The $13 million annualized expense reduction program initiated in early 2025 is clearly paying off. Q4 SG&A declined to $48.6M (33.1% of sales) from $50.0M (34.4% of sales) a year ago. This discipline allowed the company to generate a Reversing trend in profitability, turning a volatile year of earnings into a 19% YoY Q4 EBITDA jump.
Branded Products Leads SGC's Recovery
Branded Products remains the primary growth engine. The segment recorded Accelerating sales growth of 4.9% YoY ($96.9M), while segment EBITDA jumped an impressive 24% to $11.0M. Management's strategy of utilizing diverse supply bases to circumvent tariff issues and acting aggressively while smaller competitors struggle continues to win market share.
AI Technology Implementations for Efficiency
SGC's strategic investments in technology are creating operational efficiencies that competitors struggle to replicate. The use of 'Guru Assist' in the Contact Center segment for real-time agent guidance, and AI agents automating product selection and mockups in Branded Products, are critical components allowing SGC to cut SG&A without damaging the customer experience.
Healthcare Apparel Margins Collapse
A major red flag is the Decelerating performance of Healthcare Apparel. Revenue dropped 5.0% YoY to $28.8M, but more alarmingly, segment EBITDA plummeted nearly 40% YoY to just $0.64M. This indicates negative operating leverage, likely driven by the ongoing shift away from profitable institutional channels and heightened sourcing costs.
Contact Center Pipeline Yet to Materialize
Despite management touting a 'record pipeline' in Q2 and Q3, the Contact Centers segment experienced Reversing growth, with Q4 revenue falling 8.0% YoY to $21.7M. Segment EBITDA also contracted 19%. The fallout from earlier customer bankruptcies (like the Q2 solar client) appears to be outweighing new customer acquisition.
Macro Vulnerability and Tariffs
While management cited 'uncertain times' in the current release, context from prior quarters points squarely to customer purchase hesitancy induced by inflation and 'ever-escalating' tariffs. SGC is utilizing global multi-country sourcing to limit exposure, but broader economic weakness is clearly anchoring the FY26 revenue forecast.
Other KPIs
Decelerating from $33.4 million in FY24. The drop is primarily driven by working capital adjustments, including an increase in accounts receivable to $104.3M (up from $95.1M in FY24). Despite the drop, cash flow easily supported $8.9M in dividend payments and $10.1M in share repurchases.
Total debt increased from $86.0 million in FY24, comprised of $87.1M in long-term debt and $6.5M current portion. Cash equivalents rose to $23.7 million, offering $100M+ in total liquidity to pursue M&A or further buybacks.
Consolidated gross margin for the year declined from 39.0% in FY24. This reflects the intense tariff and sourcing cost pressures absorbed in H1 2025, offset partially by price increases pushed through in the second half of the year.
Guidance
Stable. The midpoint of $578.5M implies a 2.2% YoY growth rate over FY25's $566.2M. This conservative outlook suggests management anticipates ongoing softness in Healthcare and Contact Centers, relying on Branded Products to supply incremental growth.
Accelerating. The midpoint of $0.60 implies a 30% YoY increase from FY25's $0.46. This explicitly signals that SGC's newly streamlined cost structure will enable significant margin expansion even if top-line revenue remains relatively flat.
Key Questions
Healthcare Apparel Margin Compression
Healthcare Apparel EBITDA collapsed roughly 40% YoY in Q4 despite only a 5% drop in sales. What structural or sourcing issues drove this disconnect, and what is the timeline to restore profitability in this segment?
Contact Center Pipeline Conversion
In earlier quarters, management cited a 'record pipeline' for Contact Centers that was expected to convert in late 2025/early 2026. Given the 8% YoY revenue drop in Q4, are these deals still intact, or have sales cycles lengthened indefinitely?
M&A Strategy for 2026
With the balance sheet remaining robust and cash increasing to $23.7 million, does the FY26 revenue guidance of $572-$585 million account for any strategic M&A, particularly in the highly fragmented Branded Products market?